Kane Biotech Provides Business and Patent Update

WINNIPEG, MANITOBA--(Marketwired - Sept. 23, 2014) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, is providing an update to shareholders on the company's business objectives and plans.

The Company continues to focus its resources on the companion animal oral care market at this time. The objective is to establish a portfolio of products and market test these products to build and strengthen our value proposition. Additional activities included in achieving this value proposition are pricing models, market messaging, promotional material, manufacturing SOPs and the development of new applications.

We have now completed the development, testing and introduction of a number of products. Our StrixNB™ Oral Care portfolio consists of a liquid water additive, oral care spray, a single serving powder sachet and a bulk powder. In addition, we are developing and testing an oral care foam, a toothpaste, and a chew. These products will allow us to offer the market a complete and unique portfolio of products, with the potential for more products to come.

Our strategy remains to license our technology to industry leaders in both the animal and human health markets. We continue to work with potential strategic partners to advance this area of the business. While this strategy remains our priority and discussions continue it is taking longer than we had initially expected and we are no longer bound by an agreement to an exclusive option with a specific global health care company allowing us to further engage other opportunities.

In the human health care market, DispersinB® shampoo and DispersinB skin care cream have received approvals from Health Canada. Our KBI Hard Surface Disinfectant for antimicrobial claims in the ready-to-use and concentrate formulations has also received approval from Health Canada.

The Company will be conducting a financing shortly to increase our working capital to bring these products to market and drive our business forward. The financing will be supported by insiders and details will be announced at a later date.

We have also recently received two additional patents from the United States Patent and Trademark Office.

The patent entitled "Biofilm removing antimicrobial compositions and uses thereof" was issued by the U.S. Patent and Trademark Office (US Patent # 8,753,692). This patent claims the synergistic combination of sodium metaperiodate and chlorhexidine developed for antibiofilm-antimicrobial hard surface disinfectant applications for our hard surface disinfectant technology.